Adam Sharkawy

Adam is managing partner of Material Impact, a fund that seeks out transformative materials technologies and builds them into enduring companies that solve real-world problems. An accomplished healthcare and life sciences executive, Adam brings his track record of building and leading material-based centers of innovation within large companies and experience on both sides of acquisition transactions to the Material Impact team. His worldwide leadership spans US, International and Emerging Markets. Adam’s diverse background spans technologies (devices, bioactives and biologics), therapy spaces (interventional, cardiovascular, surgery and orthopedics) and business environments (VC-funded startups and Fortune 500 corporates). Prior to Material Impact, Adam was Sr. VP of The Medicines Company and Head of the Surgery and Perioperative Care Global BU where he led the $170M acquisition of Tenaxis Medical and the integration of three other acquired companies in deals totaling >$1B. Before that, he helped establish Smith & Nephew’s Emerging Market divisions in Dubai. Prior to that, he started the Advanced Healing Technologies/Biomaterials franchise within Smith & Nephew’s Endoscopy division and led the R&D organization. Adam served on the Abbott Vascular leadership team as VP of Research, Advanced Development and New Ventures where he helped launch the world’s leading Drug Eluting Stent. In addition, Adam co-led the integration of Guidant Vascular Interventions and Abbott upon their merger in 2006, when Guidant was acquired by Abbott and Boston Scientific for $28B. Adam received his Ph.D. from Duke University and his Masters from Texas A&M University. He serves on Duke's Biomedical Engineering Advisory Board and Texas A&M’s Bioengineering Advisory Board. He received his BS in Mechanical Engineering from the American University, Cairo and before that, studied pre-medicine and Biology at University of Delaware.